Hemorrhagic Shock - Pipeline Insight, 2024

Hemorrhagic Shock - Pipeline Insight, 2024

DelveInsight’s, “Hemorrhagic Shock - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hemorrhagic Shock pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hemorrhagic Shock Understanding

Hemorrhagic Shock: Overview

Hemorrhagic shock is due to the depletion of intravascular volume through blood loss to the point of being unable to match the tissues demand for oxygen. As a result, mitochondria are no longer able to sustain aerobic metabolism for the production of oxygen and switch to the less efficient anaerobic metabolism to meet the cellular demand for adenosine triphosphate. In the latter process, pyruvate is produced and converted to lactic acid to regenerate nicotinamide adenine dinucleotide (NAD+) to maintain some degree of cellular respiration in the absence of oxygen. The preponderance of hemorrhagic shock cases resulting from trauma is high. During one year, one trauma center reported 62.2% of massive transfusions occur in the setting of trauma. The remaining cases are divided among cardiovascular surgery, critical care, cardiology, obstetrics, and general surgery, with trauma utilizing over 75% of the blood products.

The body compensates for volume loss by increasing heart rate and contractility, followed by baroreceptor activation resulting in sympathetic nervous system activation and peripheral vasoconstriction. Typically, there is a slight increase in the diastolic blood pressure with narrowing of the pulse pressure. As diastolic ventricular filling continues to decline and cardiac output decreases, systolic blood pressure drops.

""Hemorrhagic Shock - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hemorrhagic Shock pipeline landscape is provided which includes the disease overview and Hemorrhagic Shock treatment guidelines. The assessment part of the report embraces, in depth Hemorrhagic Shock commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in Hemorrhagic Shock R&D. The therapies under development are focused on novel approaches to treat/improve in Hemorrhagic Shock.
• In June 2021, Akari Therapeutics working under a CRADA with the USAISR, nomacopan is currently being investigated in a model of blast injury and hemorrhagic shock. Alongside pre-clinical work, Akari is separately exploring the potential for nomacopan in traumatic brain injury and subarachnoid hemorrhage where the role of C5 and LTB4 are implicated.

This segment of the Hemorrhagic Shock report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hemorrhagic Shock Emerging Drugs

• rhMFG-E8: TheraSource

Milk fat globule epidermal growth factor-factor VIII (MFG-E8) or lactadherin is a protein produced in the human body and abundant in breast milk. TheraSource R&D team discovered that MFG-E8 has antiinflammatory activity related to an increased clearance of dead cells, reduced inflammatory signaling by immune cells, decreased accumulation of tissue-damaging neutrophils, and maintenance of epithelial integrity in the intestine. TheraSource has developed the technology to produce recombinant human protein (rhMFG-E8) with high purity, none to low toxicity and stability at 4ºC through a microbial expression system

Further product details are provided in the report……..

Hemorrhagic Shock: Therapeutic Assessment

This segment of the report provides insights about the different Hemorrhagic Shock drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hemorrhagic Shock

There are approx. 5+ key companies which are developing the therapies for Hemorrhagic Shock. The companies which have their Hemorrhagic Shock drug candidates in the most advanced stage, i.e. Preclinical include Akari Therapeutics

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Hemorrhagic Shock pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Oligonucleotide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hemorrhagic Shock: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hemorrhagic Shock therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hemorrhagic Shock drugs.

Hemorrhagic Shock Report Insights

• Hemorrhagic Shock Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hemorrhagic Shock Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hemorrhagic Shock drugs?
• How many Hemorrhagic Shock drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hemorrhagic Shock?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hemorrhagic Shock?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hemorrhagic Shock and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Nuvox
• Capricor Therapeutics
• TheraSource
• Akari Therapeutics

Key Products

• Hemorrhagic Research Project
• Engineered exosomes
• rhMFG-E8
• Nomacopan